Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients

Transplant Infectious Disease

Volumn 15, Issue 4, 2013, Pages 329-343

  Mclaughlin, J M ^a   Equils, O ^a   Somerville, K T ^a   Aram, J A ^a   Schlamm, H T ^a   Welch, V L ^a   Mardekian, J ^a   Barbers, R G ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Confounding; Heart lung transplant; Immunosuppression; Lung transplant; Non melanoma skin cancer; Risk adjustment; Statistical adjustment; Voriconazole

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; FLUCONAZOLE; ITRACONAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; TACROLIMUS; VORICONAZOLE;

ADULT; AGE; ARTICLE; ASPERGILLOSIS; CANCER PATIENT; CANCER RISK; CARDIAC GRAFT REJECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; HEART LUNG TRANSPLANTATION; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LUNG GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON MELANOMA SKIN CANCER; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEX DIFFERENCE; SUN EXPOSURE;

EID: 84880782320     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12063     Document Type: Article

References (55)

1. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002; 4 (4): 195-200.
2. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43 (Suppl 1): S49-S58.
3. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999; 78 (2): 123-138.
4. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22 (3): 258-266.
5. Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant 2009; 9 (9): 2085-2091.
6. Husain S, Paterson D, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6 (12): 3008-3016.
7. Singh N, Husain S. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S180-S191.
8. Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010; 62 (1): 31-37.
9. Brunel AS, Fraisse T, Lechiche C, Pinzani V, Mauboussin JM, Sotto A. Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy. AIDS 2008; 22 (7): 905-906.
10. Epaulard O, Saint-Raymond C, Villier C, et al. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients. Clin Microbiol Infect 2010; 16 (9): 1362-1364.
11. McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007; 44 (5): e55-e56.
12. Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010; 146 (3): 300-304.
13. Morice C, Acher A, Soufir N, et al. Multifocal aggressive squamous cell carcinomas induced by prolonged voriconazole therapy: a case report. Case Report Med 2010; 2010: 351084.
14. Vanacker A, Fabre G, Van Dorpe J, Peetermans WE, Maes B. Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient. Am J Transplant 2008; 8 (4): 877-880.
15. Vadnerkar A, Nguyen MH, Mitsani D, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29 (11): 1240-1244.
16. Feist A, Osborne S, Thistlethwaite P, Madani M, Yung G. Voriconazole Use Increases the Incidence of Skin Cancer in Lung Transplant Patients. Am J Respir Crit Care Med 2009; 179 (ATC Meeting Abstracts): A4589.
17. Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012; 31 (7): 694-699.
18. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167 (4): 492-499.
19. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164 (4): 580-584.
20. Otley CC, Cherikh WS, Salasche SJ, McBride MA, Christenson LJ, Kauffman HM. Skin cancer in organ transplant recipients: effect of pretransplant end-organ disease. J Am Acad Dermatol 2005; 53 (5): 783-790.
21. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47 (11): 1245-1251.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 (5): 373-383.
23. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 129 (1): 125-137.
24. Chuang TY, Popescu A, Su WP, Chute CG. Basal cell carcinoma. A population-based incidence study in Rochester, Minnesota. J Am Acad Dermatol 1990; 22 (3): 413-417.
25. Fears TR, Scotto J, Schneiderman MA. Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States. Am J Epidemiol 1977; 105 (5): 420-427.
26. Gupta AK, Cardella CJ, Haberman HF. Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol 1986; 122 (11): 1288-1293.
27. Kopf AW. Computer analysis of 3531 basal-cell carcinomas of the skin. Nihon Hifuka Gakkai Zasshi 1979; 89 (13): 897-911.
28. Roenigk RK, Ratz JL, Bailin PL, Wheeland RG. Trends in the presentation and treatment of basal cell carcinomas. J Dermatol Surg Oncol 1986; 12 (8): 860-865.
29. Scotto J, Fears TR, Fraumeni JF Jr. Incidence of nonmelanoma skin cancer in the United States. NIH Publication No. 83-2433. National Institutes of Health: Bethesda, Maryland, 1983.
30. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985; 78 (1A): 44-49.
31. Penn I. Cancers after cyclosporine therapy. Transplant Proc 1988; 1 (Suppl 1): 276-279.
32. Lindqvist C. Risk factors of lip cancer: a critical evaluation based on epidemiological comparisons. Am J Public Health 1979; 69 (3): 256-260.
33. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 2003; 49 (3): 397-406.
34. Caforio AL, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 19 (Suppl 3): III222-III227.
35. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26 (6): 976-990.
36. Neoh CF, Snell GI, Kotsimbos T, et al. Antifungal prophylaxis in lung transplantation-a world-wide survey. Am J Transplant 2011; 11 (2): 361-366.
37. El-Hamamsy I, Stevens LM, Carrier M, et al. Incidence and prognosis of cancer following heart transplantation using RATG induction therapy. Transpl Int 2005; 18 (11): 1280-1285.
38. Geusau A, Dunkler D, Messeritsch E, et al. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy. Int J Dermatol 2008; 47 (9): 918-925.
39. Bichari W, Bartiromo M, Mohey H, et al. Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases. Transplant Proc 2009; 41 (2): 672-673.
40. Altman A, Rosen T, Tschen JA, et al. Basal cell epithelioma in black patients. J Am Acad Dermatol 1987; 1 (5 Pt 1): 741-745.
41. Emmett EA. Ultraviolet radiation as a cause of skin tumors. CRC Crit Rev Toxicol 1973; 2 (2): 211-255.
42. Giles GG, Marks R, Foley P. Incidence of non-melanocytic skin cancer treated in Australia. Br Med J (Clin Res Ed) 1988; 296 (6614): 13-17.
43. Leong GK, Stone JL, Farmer ER, et al. Nonmelanoma skin cancer in Japanese residents of Kauai, Hawaii. J Am Acad Dermatol 1987; 17 (2 Pt 1): 233-238.
44. Silverstone H, Searle JH. The epidemiology of skin cancer in Queensland: the influence of phenotype and environment. Br J Cancer 1970; 24 (2): 235-252.
45. Delgado M, Fernandez R, Paradela M, et al. Development of neoplasms during lung transplantation follow-up. Transplant Proc 2008; 40 (9): 3094-3096.
46. Amital A, Shitrit D, Raviv Y, et al. Development of malignancy following lung transplantation. Transplantation 2006; 81 (4): 547-551.
47. Stagner LD, Allenspach LL, Hogan KK, Willcock LC, Higgins RS, Chan KM. Bronchogenic carcinoma in lung transplant recipients. J Heart Lung Transplant 2001; 20 (8): 908-911.
48. Robbins HY, Arcasoy SM. Malignancies following lung transplantation. Clin Chest Med 2011; 32 (2): 343-355.
49. Denning DW, Griffiths CE. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 2001; 26 (8): 648-653.
50. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347 (6): 408-415.
51. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34 (5): 563-571.
52. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36 (5): 630-637.
53. Rubenstein M, Levy ML, Metry D. Voriconazole-induced retinoid-like photosensitivity in children. Pediatr Dermatol 2004; 21 (6): 675-678.
54. Vandecasteele SJ, Van Wijngaerden E, Peetermans WE. Two cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazole. Eur J Clin Microbiol Infect Dis 2004; 23 (8): 656-657.
55. Racette AJ, Roenigk HH Jr, Hansen R, Mendelson D, Park A. Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl. J Am Acad Dermatol 2005; 5 (Suppl 1): S81-S85.